remain posit management commentari provid us greater confid
approv close aet merger also quantifi rebat retent
management remov overhang relat potenti loss rebat
weigh share late despit share appreci follow earn call
continu believ valuat look compel
expect management provid updat regard pend acquisit aet
appear progress along nice management note date substanti number
state approv merger expect approv summer
alreadi held schedul hear said state may wait doj
decis render addit management note determin
potenti impact divestitur medicar part materi deal
model furthermor management provid specif expect regard close
transact indic us management receiv enough feedback
regul feel confid gain approv close transact within
next month management expect close acquisit late earli
compar previou expect second-half
management re-affirmed valu caremark bring custom face current drug
price debat center around loss safe harbor protect rebat
notabl management state return custom rebat retain
rebat annual adj ep rebat less
like street estim posit investor
quantifi rebat help remov overhang loss rebat weigh
share late management note caremark abl keep drug
trend improv adher well caremark custom saw drug trend
per capita despit awp inflat nearli management also estim
pbm techniqu save health care system next decad
furthermor management point yesterday announc offer medicar
advantag plan option appli step therapi physician-administ
part drug valid pbm tool thu valu pbm bring health care
sell season appear progress well report gross win
net win complet client renew roughli in-
line previou year notabl management report current retent rate slightli
higher previou year think like due favor opinion current
caremark custom consist result employ survey addit
extend fep retail mail contract one year beyond
extens announc earlier year
pleas see page report import disclosur
current invest thesi lie acquisit aet view favor
think care coordin combin entiti posit well value-
base care addit share look under-valued current level pro forma basi
mani may overlook fact consensu estim lack contribut
aet furthermor share even look attract stand-alone basi also see upsid
estim revenu synergi opportun see favor risk/reward
 progress regulatori approv
process pend acquisit aet
 top-lin growth retail/ltc
revenu pbm revenu
 oper margin modestli
y/i due increment oper expens
reinvest mix shift toward
pbm segment
 assum share repo
 strong retail comp better macro
environ coupl better pbm
 stronger gener lower
 sooner expect close aet
debt paydown greater
 slower expect growth
 weaker expect gener
greater expect reimburs
 less expect debt paydown
one largest drug retail chain compani larg oper
two main busi segment pharmaci servic retail pharmaci
retail pharmaci segment compani oper drugstor on-line retail
pharmaci websit well health clinic store sell prescript drug
wide array gener merchandis refer front end product
compani also provid full rang pbm servic client mainli includ
organ sponsor health benefit plan servic includ formulari
servic diseas manag program pharmacogenom servic
valuat remain compel current level
despit appreci share today continu believ valuat look
compel pro forma basi share current trade updat
pro forma adj ep estim believ mani overlook fact
consensu adj ep estim fulli reflect contribut
aet even look consensu estim share look attract current
trade consensu adj ep
rais adj ep estim
respect said maintain price target base revis dcf
analysi impli share trade adj ep estim
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang net work termin valuefre pv npv free futur excess valu total number valu per year end decemb cowen
million except per-shar data
compani report cowen compani
interseg good interseg cost good gener amort ex-deal oper expens tax provis tax incom continu incom intang earli extinguish discontinu loss non-controlling financ wtd averag ep cont chang year end decemb cowen
million except per-shar data
compani report cowen compani
interseg good interseg cost good gener amort ex-deal oper expens tax provis tax incom continu incom alloc particip intang earli extinguish discontinu loss non-controlling financ wtd averag ep cont chang cowen
million
compani report cowen compani
asset cash receiv incom current equip asset liabil account discount portion long-term current incom non-curr non-controlling equiti common held comprehens sharehold sharehold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end decemb cowen
million
compani report cowen compani
income/ loss flow oper activ depreci stock-bas loss earli extinguish debt- sale subsidiary- defer incom tax non-cash chang oper asset liabil account receiv current account accru long-term net cash oper acquisit properti acquisit issuance/ repurchas common purchas treasuri stock- dividend proceeds/ purchas secur proceeds/ repay debt other- net increase/ decreas cash equival begin cash equival end cowen summari oper capit owner financ non-recur exclud non-recur itemsfor year end decemb cowen
million
compani report cowen compani
flow oper activ net adjust reconcil net earn net cash depreci goodwil impairment- loss settlement defin benefit pension plans- stock-bas loss earli extinguish debt- sale subsidiary- defer incom tax non-cash chang oper asset liabil account receiv current account accru long-term net cash provid oper flow invest activitiespurchas properti proce sale-lease-back proce sale properti acquisit net cash acquir purchas available-for-sal sale short-term investments- sale matur available-for-sal proce sale subsidiary- proce sale dispos assets- net cash use invest flow financ activitiesincreas decreas short-term repay debt assum acquisition- proce issuanc long-term repay long-term debt- purchas non-controlling interest subsidiary- dividend deriv settlements- proce exercis stock excess tax benefit stock-bas repurchas common net cash provid use financ effect exchang rate cash- net decreas cash cash cash equival begin cash equival end year end decemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
lack regulatori approv acquisit aet challeng
later expect roll-on contract
